Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Bevacizumab
Related studies linked through entity extraction aliases.
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
- Status
- COMPLETED
- Phase
- PHASE1
Bevacizumab in Treating Young Patients With Refractory Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
- Status
- COMPLETED
- Phase
- PHASE3
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE3